175 related articles for article (PubMed ID: 15946219)
1. A new functional assay of thrombin activatable fibrinolysis inhibitor.
Guimarães AH; Bertina RM; Rijken DC
J Thromb Haemost; 2005 Jun; 3(6):1284-92. PubMed ID: 15946219
[TBL] [Abstract][Full Text] [Related]
2. Increased zymogen activity of thrombin-activatable fibrinolysis inhibitor prolongs clot lysis.
Mishra N; Buelens K; Theyskens S; Compernolle G; Gils A; Declerck PJ
J Thromb Haemost; 2012 Jun; 10(6):1091-9. PubMed ID: 22498006
[TBL] [Abstract][Full Text] [Related]
3. Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model.
Guimarães AH; Rijken DC
Thromb Haemost; 2004 Mar; 91(3):473-9. PubMed ID: 14983222
[TBL] [Abstract][Full Text] [Related]
4. Association between thrombin activatable fibrinolysis inhibitor genotype and levels in plasma: comparison of different assays.
Guimarães AH; van Tilburg NH; Vos HL; Bertina RM; Rijken DC
Br J Haematol; 2004 Mar; 124(5):659-65. PubMed ID: 14871254
[TBL] [Abstract][Full Text] [Related]
5. The role of thrombin activatable fibrinolysis inhibitor in arterial thrombosis at a young age: the ATTAC study.
de Bruijne EL; Gils A; Guimarães AH; Dippel DW; Deckers JW; van den Meiracker AH; Poldermans D; Rijken DC; Declerck PJ; de Maat MP; Leebeek FW
J Thromb Haemost; 2009 Jun; 7(6):919-27. PubMed ID: 19323787
[TBL] [Abstract][Full Text] [Related]
6. Two naturally occurring variants of TAFI (Thr-325 and Ile-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme.
Schneider M; Boffa M; Stewart R; Rahman M; Koschinsky M; Nesheim M
J Biol Chem; 2002 Jan; 277(2):1021-30. PubMed ID: 11684677
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibodies targeting the antifibrinolytic activity of activated thrombin-activatable fibrinolysis inhibitor but not the anti-inflammatory activity on osteopontin and C5a.
Semeraro F; Ammollo CT; Gils A; Declerck PJ; Colucci M
J Thromb Haemost; 2013 Dec; 11(12):2137-47. PubMed ID: 24134522
[TBL] [Abstract][Full Text] [Related]
8. Elucidation of the molecular mechanisms of two nanobodies that inhibit thrombin-activatable fibrinolysis inhibitor activation and activated thrombin-activatable fibrinolysis inhibitor activity.
Zhou X; Weeks SD; Ameloot P; Callewaert N; Strelkov SV; Declerck PJ
J Thromb Haemost; 2016 Aug; 14(8):1629-38. PubMed ID: 27279497
[TBL] [Abstract][Full Text] [Related]
9. Thrombin-activable fibrinolysis inhibitor zymogen does not play a significant role in the attenuation of fibrinolysis.
Foley JH; Kim P; Nesheim ME
J Biol Chem; 2008 Apr; 283(14):8863-7. PubMed ID: 18252711
[TBL] [Abstract][Full Text] [Related]
10. Effect of warfarin treatment on thrombin activatable fibrinolysis inhibitor (TAFI) activation and TAFI-mediated inhibition of fibrinolysis.
Incampo F; Carrieri C; Galasso R; Scaraggi FA; Di Serio F; Woodhams B; Semeraro N; Colucci M
J Thromb Haemost; 2013 Feb; 11(2):315-24. PubMed ID: 23256818
[TBL] [Abstract][Full Text] [Related]
11. Thrombin activatable fibrinolysis inhibitor (TAFI) does not inhibit in vitro thrombolysis by pharmacological concentrations of t-PA.
Colucci M; D'Aprile AM; Italia A; Gresele P; Morser J; Semeraro N
Thromb Haemost; 2001 Apr; 85(4):661-6. PubMed ID: 11341502
[TBL] [Abstract][Full Text] [Related]
12. Hyperprothrombinemia associated with prothrombin G20210A mutation inhibits plasma fibrinolysis through a TAFI-mediated mechanism.
Colucci M; Binetti BM; Tripodi A; Chantarangkul V; Semeraro N
Blood; 2004 Mar; 103(6):2157-61. PubMed ID: 14630828
[TBL] [Abstract][Full Text] [Related]
13. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis.
Colucci M; Binetti BM; Branca MG; Clerici C; Morelli A; Semeraro N; Gresele P
Hepatology; 2003 Jul; 38(1):230-7. PubMed ID: 12830006
[TBL] [Abstract][Full Text] [Related]
14. Dabigatran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombin-activatable fibrinolysis inhibitor.
Ammollo CT; Semeraro F; Incampo F; Semeraro N; Colucci M
J Thromb Haemost; 2010 Apr; 8(4):790-8. PubMed ID: 20088944
[TBL] [Abstract][Full Text] [Related]
15. Generation of a stable activated thrombin activable fibrinolysis inhibitor variant.
Ceresa E; Van de Borne K; Peeters M; Lijnen HR; Declerck PJ; Gils A
J Biol Chem; 2006 Jun; 281(23):15878-83. PubMed ID: 16595693
[TBL] [Abstract][Full Text] [Related]
16. Lys 42/43/44 and Arg 12 of thrombin-activable fibrinolysis inhibitor comprise a thrombomodulin exosite essential for its antifibrinolytic potential.
Wu C; Stafford AR; Fredenburgh JC; Weitz JI; Gils A; Declerck PJ; Kim PY
Thromb Haemost; 2017 Jul; 117(8):1509-1517. PubMed ID: 28640323
[TBL] [Abstract][Full Text] [Related]
17. Reversible inhibitors of TAFIa can both promote and inhibit fibrinolysis.
Schneider M; Nesheim M
J Thromb Haemost; 2003 Jan; 1(1):147-54. PubMed ID: 12871552
[TBL] [Abstract][Full Text] [Related]
18. Association between thrombin-activatable fibrinolysis inhibitor (TAFI) and clinical outcome in patients with unstable angina pectoris.
Brouwers GJ; Leebeek FW; Tanck MW; Wouter Jukema J; Kluft C; de Maat MP
Thromb Haemost; 2003 Jul; 90(1):92-100. PubMed ID: 12876631
[TBL] [Abstract][Full Text] [Related]
19. High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke.
Leebeek FW; Goor MP; Guimaraes AH; Brouwers GJ; Maat MP; Dippel DW; Rijken DC
J Thromb Haemost; 2005 Oct; 3(10):2211-8. PubMed ID: 16092924
[TBL] [Abstract][Full Text] [Related]
20. Relationship Between Polymorphism of Thrombin-Activatable Fibrinolysis Inhibitor Gene +1040C/T and a Cohort of Chinese Women With Recurrent Spontaneous Abortion.
Fang P; Cai D; Du L; Shen F; Zhang C; Li M
Clin Appl Thromb Hemost; 2021; 27():10760296211029720. PubMed ID: 34189940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
